ERBB2 and breast cancer: The primary objectives of the TRYPHAENA trial were to assess the cardiac tolerability of neoadjuvant pertuzumab and trastuzumab given with anthracycline containing or anthracycline free standard chemotherapy in HER2-positive breast cancer, and compare pathologic response rates among the different treatment groups [9]. The CLEOPATRA trial was a phase III trial that looked at the combination of trastuzumab and pertuzumab and taxane in women with HER2-postive metastatic breast cancer [7].